Analyst Price Targets — LXEO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 13, 2026 11:15 am | Mitchell Kapoor | H.C. Wainwright | $10.00 | $8.12 | TheFly | Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright |
| December 17, 2025 9:09 pm | — | Raymond James | $25.00 | $9.11 | TheFly | Lexeo Therapeutics initiated with a Strong Buy at Raymond James |
| December 10, 2025 11:38 am | Leland Gershell | Oppenheimer | $20.00 | $9.51 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Lexeo Therapeutics (LXEO) |
| November 20, 2025 1:28 pm | — | Cantor Fitzgerald | $19.00 | $9.09 | TheFly | Lexeo Therapeutics initiated with an Overweight at Cantor Fitzgerald |
| October 21, 2025 10:24 am | — | H.C. Wainwright | $13.00 | $9.22 | TheFly | Lexeo Therapeutics price target lowered to $13 from $15 at H.C. Wainwright |
| October 15, 2025 10:24 am | — | Guggenheim | $30.00 | $8.50 | TheFly | Lexeo Therapeutics initiated with a Buy at Guggenheim |
| October 7, 2025 4:18 pm | — | Chardan Capital | $17.00 | $8.25 | TheFly | Lexeo Therapeutics price target raised to $17 from $15 at Chardan |
| October 7, 2025 3:08 pm | — | H.C. Wainwright | $15.00 | $8.25 | TheFly | Lexeo Therapeutics price target raised to $15 from $9 at H.C. Wainwright |
| October 7, 2025 2:05 pm | Mani Foroohar | Leerink Partners | $20.00 | $8.25 | TheFly | Lexeo Therapeutics price target raised to $20 from $9 at Leerink |
| June 12, 2024 4:12 pm | Brian Skorney | Robert W. Baird | $28.00 | $18.19 | TheFly | Lexeo Therapeutics initiated with an Outperform at Baird |
Latest News for LXEO
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September: Cantor Global Healthcare Conference 2026.
Avoro Capital Advisors LLC purchased a new stake in Lexeo Therapeutics, Inc. (NASDAQ: LXEO) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 1,489,189 shares of the company's stock, valued at approximately $6,932,175,000. Lexeo Therapeutics makes up 0.1% of Avoro Capital Advisors LLC's
Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identification of eligible participants for SUNRISE-FA 2 FDA granted RMAT designation…
RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LXEO.
U.S. House Trading
No House trades found for LXEO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.